By Cassius "Broadside" Quill
More than 90,000 Americans are on the waiting list for a kidney transplant, according to the Organ Procurement and Transplantation Network (OPTN), the federally contracted registry that tracks U.S. transplant data. Roughly a dozen of them die each day before one becomes available, a figure drawn from HRSA's organdonor.gov. That grim arithmetic has revived a debate that has simmered in medical ethics and economics circles for decades: should the United States allow people to be paid for donating a kidney, the way they are already compensated for donating blood, plasma, or eggs, or for enrolling in risky drug trials? The 1984 National Organ Transplant Act bans the sale of organs, but a growing chorus of economists, bioethicists, and even some transplant surgeons argue it's time to reconsider — while others warn that putting a price on body parts would be a moral and practical disaster.
A note on sourcing: this piece surveys a live policy argument rather than reporting new facts. Where claims below are attributed to unnamed "proponents," "critics," or "opponents," that reflects the general shape of the public debate as it's commonly summarized — not a single named economist, bioethicist, or paper we can point you to. Readers should weigh those passages accordingly.
The case for compensating donors
Proponents argue the shortage is not an accident of nature but a policy choice. We already pay people for blood plasma, sperm, eggs, and participation in clinical trials that carry real physical risk — kidney donation, they note, is comparably safe, with a healthy remaining kidney typically sufficient for a normal life. If compensation is ethically acceptable for those other bodily contributions, the argument goes, it's inconsistent to treat kidneys as uniquely untouchable while thousands die waiting.
Supporters often point to Iran, which they describe as the only country with a regulated, compensated donor system, and claim it has effectively eliminated its kidney waiting list. We should flag this plainly: that claim, as widely repeated as it is, traces in this piece to no single named study, economist, or report we can verify — it should be read as an oft-cited talking point among advocates, not an established fact. Supporters also argue that altruism alone has never come close to meeting demand, though the specific claim that U.S. living-donation rates have been flat for years despite awareness campaigns is one OPTN's own historical donation figures could confirm or complicate — we have not independently checked that trend line here, and readers should treat it as an assertion, not a verified data point. A modest payment — some proposals suggest a tax credit, a lifetime health-insurance guarantee, or a fixed government-administered stipend rather than an open market — could close that gap without turning organs into a Wall Street commodity. Crucially, most serious proposals call for a single-payer, government-regulated system, not a free-for-all bazaar, precisely to guard against exploitation. Advocates frame this as a matter of bodily autonomy: adults are trusted to make far riskier and more consequential decisions about their own bodies, and denying them the choice to be compensated for a low-risk, life-saving act is paternalism dressed up as ethics.
The case against a kidney market
Opponents counter that even a "regulated" payment system would functionally create a market in human body parts, and markets have a way of expanding beyond their original guardrails. Their deepest worry is about who would actually sell: not the affluent, but people in financial distress, for whom a payment offer is less a free choice than a pressure they can't afford to refuse. Critics say Iran's system draws disproportionately from its poorest citizens — again, a characterization we can attribute to critics of the model rather than to a specific documented study cited in this piece — and point to reports of donor regret, unaddressed post-surgical complications, and inadequate follow-up care that complicate the picture proponents cite as success.
There is also a slippery-slope concern rooted in medical history: transplant medicine has long guarded against any perception that a patient's organs have a price, precisely because that perception erodes public trust in the entire donation system — including the altruistic deceased-donor network that supplies the majority of transplants today. If kidneys can be bought, critics ask, why not corneas, portions of livers, or bone marrow, and where does society draw the line between compensating a "gift" and commodifying a person? Some also raise concerns about coercion within families and communities — pressure on a poorer relative to "volunteer" — that a well-intentioned government stipend wouldn't necessarily eliminate. For many opponents, the right response to the shortage is more investment in the deceased-donor system, opt-out registries, or expanded eligibility criteria — not a price tag on the body.
The unresolved tension
Both sides agree the status quo is failing patients; they disagree sharply about what "consent" and "exploitation" mean when money and mortality are both on the table. Supporters trust individuals to weigh a life-saving trade for themselves and see current law as a paternalistic barrier costing lives. Opponents see structural pressures that no regulation can fully neutralize, and fear that treating organs as goods would corrode a system built on gift and trust. The open question is whether a carefully bounded, government-run compensation model can capture the life-saving upside proponents describe while avoiding the exploitation opponents fear — or whether, once a price is set, the distinction between donation and sale simply disappears. Readers weighing this debate deserve better than we've fully delivered here: the named studies, economists, and transplant surgeons behind each claim belong in any serious follow-up.
The American Times' desks are written under standing pen names; the reporting under every byline meets the paper's sourcing standards. See "About Our Bylines."